Качество жизни – важный критерий эффективности таргетной терапии метастатического поражения скелета при раке молочной железы

Оценка качества жизни является важным, надежным, информативным и экономичным методом, позволяющим определить эффективность лечения больных раком молочной железы с метастазами в кости, получающих терапию остеомодифицирующи- ми агентами, в том числе таргетную терапию деносумабом. Использование деносумаба значимо повышает качество жизни больных раком молочной железы с метастазами в кости, в том числе поддерживая общий статус больного, снижая интенсивность болевого синдрома, и предупреждает развитие костных осложнений: патологических переломов, компрессии спинного мозга, гиперкальциемии, а также необходимость лучевой терапии или хирургического лечения по поводу метастазов в кости.

качество жизни, рак молочной железы, метастазы в кости, костные осложнения, деносумаб, золедроновая кислота

1. Мерабишвили В.М. Рак молочной железы: заболеваемость, смертность, выживаемость (популяционное исследование). Вопр онкол 2011;57(5):609–15.

2. Fisher B., Osborn K., Margolese R. et al. Neoplasms of the breast. In: Cancer medicine. 3rd ed. Ed. by J. Holland et al. 1993. Рp. 1706–74. 3. Theoleyre S., Wittrant Y., Tat S.K. et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004;15(6):457–75.

3. Kearns A.E., Khosla S., Kostenuik P.J. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008;29(2):155–92.

4. Wright H.L., McCarthy H.S., Middleton J., Marshall M.J. RANK, RANKL and osteoprotegerinin bone biology and disease. Curr Rev Musculoskelet Med 2009;2(1):56–64.

5. Body J.J., Greipp P., Coleman R.E. et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer

6. ;97(3 Suppl):887–92.

7. Stopeck A.T., Lipton A., Body J.J. et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28(35):5132–9.

8. Levren G., Sadik M., Gjertsson P. et al. Relation between pain and skeletal metastasis in patients with prostate or breast cancer. Clin Physiol Funct Imaging 2011;31(3):193–5.

9. Pecherstorfer M., Jilch R., Sauty A. et al. Effect of first treatment with aminobisphosphonates pamidronate and ibandronate in circulating lymphocyte subpopulations. J Bone Min Res 2000;15(1):147–54.

10. Clare C., Royle D., Saharia K. et al. Painful bone metastases: a prospective observational cohort study. Palliat Med 2005;19(7):521–5.

11. Kanis J.A., Johansson H., Oden A., McCloskey E.V. Assessment of fracture risk. Eur J Radiol 2009;71(3):392–7.

12. Weinfurt K.P., Li Y., Castel L.D. et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16(4):579–84.

13. Coleman R.E. Bisphosphonates: clinical experience. Oncologist 2004;9 Suppl 4:14–27.

14. Costa L., Badia X., Chow E. et al. Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer 2008;16(8):879–89.

15. Weinfurt K.P., Castel L.D., Li Y. et al. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 2004;42(2):164–75.

16. Pockett R.D., Castellano D., McEwan P.

17. et al. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl) 2010;19(6):755–60.

18. Coward D.D., Wilkie D.J. Metastatic bone pain. Meanings associated with self-report and self-management decision making. Cancer Nurs 2000;23(2):101–8.

19. Ионова Т.И., Новик А.А., Сухонос Ю.А. Понятие качества жизни больных онкологического профиля. Онкология 2000;2(1–2):25–8.

20. Aaronson N.K., Cull A., Kaasa S., Sprangers M. The European Organisation for Research and Treatment of Cancer (EORTC) modular approach to quality of life assessment in oncology. Int J Ment Health 1994;23:75–96.

21. Wardley A., Davidson N., Barrett-Lee P. et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005;92(10):1869–76.

22. Body J.J., Diel I.J., Bell R. et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004;111(3):306–12.

23. Martin M., Bell R., Bourgeois H. et al. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res 2012;18(17):4841–9.

24. Diel I.J., Bergner R., Grötz K.A. Adverse effects of bisphosphonates: current issues. J Support Oncol 2007;5(10):475–82.

25. Perazella M.A., Markowitz G.S. Bisphosphonate nephrotoxicity. Kidney Int 2008;74(11):1385–93.

26. Tabrizi M.A., Tseng C.M., Roskos L.K. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006;11(1–2):81–8.

27. King A.E., Umland E.M. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacotherapy 2008;28(5):667–77.

28. Cavanna L., Bertè R., Arcari A. et al. Osteonecrosis of the jaw. A newly emerging site- specific osseous pathology in patients with cancer treated with bisphosphonates. Report of five cases and review of the literature. Eur J Intern Med 2007;18(5):417–22.

29. Marx R.E., Sawatari Y., Fortin M., Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63(11):1567–75.

30. Saad F., Brown J.E., C. Van Poznak С. et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012;23(5):1341–47.

31. Harris K., Chow E., Zhang L. et al. Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastases. Eur J Cancer 2009;45(14):2510–8.